HomeInsightsStock Comparison

Cohance Lifesciences Ltd vs Wockhardt Ltd Stock Comparison

Cohance Lifesciences Ltd vs Wockhardt Ltd Stock Comparison

Last Updated on: Jul 22, 2025

Key Highlights

  • The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 1063 as of 22 Jul 15:30.
  • The P/E Ratio of Cohance Lifesciences Ltd changed from 8.1 on March 2020 to 0 on March 2025 . This represents a CAGR of -100.00% over 6 yearsThe P/E Ratio of Wockhardt Ltd changed from 6.6 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years.
  • The Market Cap of Cohance Lifesciences Ltd changed from ₹ 2564 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 6 yearsThe Market Cap of Wockhardt Ltd changed from ₹ 1912 crore on March 2020 to ₹ 23133 crore on March 2025 . This represents a CAGR of 51.50% over 6 years.
  • The revenue of Cohance Lifesciences Ltd for the Mar '25 is ₹ 412.59 crore as compare to the Dec '24 revenue of ₹ 322.86 crore. This represent the growth of 27.79% The revenue of Wockhardt Ltd for the Mar '25 is ₹ 758 crore as compare to the Dec '24 revenue of ₹ 729 crore. This represent the growth of 3.98%.
  • The ebitda of Cohance Lifesciences Ltd for the Mar '25 is ₹ 84.13 crore as compare to the Dec '24 ebitda of ₹ 133.41 crore. This represent the decline of -36.94% The ebitda of Wockhardt Ltd for the Mar '25 is ₹ 79 crore as compare to the Dec '24 ebitda of ₹ 136 crore. This represent the decline of -41.91%.
  • The net profit of Cohance Lifesciences Ltd changed from ₹ 120.59 crore to ₹ 38.73 crore over 8 quarters. This represents a CAGR of -43.33% The net profit of Wockhardt Ltd changed from ₹ -136 crore to ₹ -45 crore over 8 quarters. This represents a CAGR of -42.48% .
  • The Dividend Payout of Cohance Lifesciences Ltd changed from 23.57 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 yearsThe Dividend Payout of Wockhardt Ltd changed from 0 % on March 2020 to 0 % on March 2025 . This represents a CAGR of 0.0% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cohance Lifesciences Ltd

  • Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
  • The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

About Wockhardt Ltd

  • Wockhardt Limited, incorporated in July, 1999 is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world.
  • The Company is India's leading research-based global healthcare enterprise in fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals.
  • It has 12 manufacturing locations and there are 3 locations where research and development activities are carried out. The Company has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland.
  • It has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses.
  • Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified lnfectious Diseases Programme) for 5 of Anti-bacterial discovery programmes - 2 of them are Gram Negative and 3 Gram Positive effective against untreatable 'Superbugs'.

Cohance Lifesciences Ltd News Hub

News

Cohance Lifesciences to announce Quarterly Result

Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 13 Au...

Read more

28 Jun 2025 09:56

News

Cohance Lifesciences to hold AGM

Cohance Lifesciences announced that the 7th Annual General Meeting(AGM) of the company wil...

Read more

27 Jun 2025 15:41

News

Cohance Lifesciences' API Unit-IV clears USFDA inspection

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the Unite...

Read more

26 May 2025 08:46

News

Suven Pharmaceuticals allots 12.80 cr equity shares

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value...

Read more

09 May 2025 09:58

News

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of Indi...

Read more

08 May 2025 09:39

News

Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation

Suven Pharmaceuticals announced that it has received final approval from the Department of...

Read more

26 Apr 2025 12:56

Wockhardt Ltd News Hub

News

Wockhardt to hold AGM

Wockhardt announced that the 26th Annual General Meeting(AGM) of the company will be held ...

Read more

17 Jul 2025 16:03

News

Wockhardt climbs on exiting US generics to refocus on innovation

The move is aimed at realigning focus toward high-impact areas, including novel antibiotic...

Read more

14 Jul 2025 17:12

News

Wockhardt undertakes realignment of its US business

Wockhardt is undertaking significant strategic realignment of its US business in line with...

Read more

11 Jul 2025 16:28

News

Wockhardt to conduct board meeting

Wockhardt will hold a meeting of the Board of Directors of the Company on 29 May 2025. Pow...

Read more

24 May 2025 18:26

News

Wockhardt announces incorporation of step-down subsidiary in Ireland

Wockhardt Bio AG, a subsidiary of Wockhardt, has incorporated a new Wholly Owned Subsidiar...

Read more

08 Apr 2025 19:55

News

Wockhardt surges after breakthrough US cancer treatment with Zaynich

The 15-year-old patient, diagnosed with Acute Myeloid Leukemia (AML), had been battling a ...

Read more

01 Apr 2025 11:32

SWOT Analysis Of Wockhardt Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Cohance Lifesciences Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Wockhardt Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Cohance Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cohance Lifesciences Ltd and Wockhardt Ltd

Which company has a larger market capitalization, Cohance Lifesciences Ltd or Wockhardt Ltd?

Market cap of Cohance Lifesciences Ltd is 40,988 Cr while Market cap of Wockhardt Ltd is 28,205 Cr

What are the key factors driving the stock performance of Cohance Lifesciences Ltd and Wockhardt Ltd?

The stock performance of Cohance Lifesciences Ltd and Wockhardt Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cohance Lifesciences Ltd and Wockhardt Ltd?

As of July 22, 2025, the Cohance Lifesciences Ltd stock price is INR ₹1071.4. On the other hand, Wockhardt Ltd stock price is INR ₹1735.85.

How do dividend payouts of Cohance Lifesciences Ltd and Wockhardt Ltd compare?

To compare the dividend payouts of Cohance Lifesciences Ltd and Wockhardt Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions